{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:31:31Z","timestamp":1788546691046,"version":"build-2803163510"},"reference-count":29,"publisher":"Becaris Publishing Limited","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    Herein, we report safety outcomes for varenicline solution nasal spray (VNS) within the context of clinical trial discontinuation, contrasting those with discontinuation outcomes from topical cyclosporine and lifitegrast clinical trials.\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    1061 subjects were randomized across three clinical trials to receive either VNS 0.06\u00a0mg, VNS 0.03\u00a0mg, VNS 0.006\u00a0mg or vehicle control. Subjects who discontinued from treatment were noted and assigned to their appropriate categories.\n                    <jats:bold>Results:<\/jats:bold>\n                    Despite treatment emergent adverse events, 93.5% of subjects receiving VNS completed the treatment period. By comparison, only 80% of subjects in the integrated clinical trials for cyclosporine ophthalmic emulsion and 91% of subjects in the integrated trials for lifitegrast ophthalmic solution completed the full treatment period, respectively.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    In clinical trials, VNS demonstrated improvements in dry eye disease signs and symptoms, was well-tolerated, and had an overall completion rate &gt;93%. Conventional dry eye treatments (e.g., cyclosporine and lifitegrast) noted considerably higher discontinuation rates in their clinical trials.\n                  <\/jats:p>","DOI":"10.57264\/cer-2022-0215","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T08:15:00Z","timestamp":1682410500000},"source":"Crossref","is-referenced-by-count":9,"title":["Safety, adherence and discontinuation in varenicline solution nasal spray clinical trials for dry eye disease"],"prefix":"10.57264","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9392-4998","authenticated-orcid":false,"given":"Scott G","family":"Hauswirth","sequence":"first","affiliation":[{"name":"University of Colorado, Anschutz Medical Campus, Aurora, CO\u00a080045, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7916-6166","authenticated-orcid":false,"given":"Alan G","family":"Kabat","sequence":"additional","affiliation":[{"name":"Oyster Point Pharmaceuticals, Princeton, NJ\u00a008540, USA"},{"name":"Salus University, Elkins Park, PA\u00a019027, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5542-2399","authenticated-orcid":false,"given":"Mandy","family":"Hemphill","sequence":"additional","affiliation":[{"name":"Oyster Point Pharmaceuticals, Princeton, NJ\u00a008540, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan","family":"Somaiya","sequence":"additional","affiliation":[{"name":"Oyster Point Pharmaceuticals, Princeton, NJ\u00a008540, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura H","family":"Hendrix","sequence":"additional","affiliation":[{"name":"Oyster Point Pharmaceuticals, Princeton, NJ\u00a008540, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1655-6973","authenticated-orcid":false,"given":"Andrea A","family":"Gibson","sequence":"additional","affiliation":[{"name":"Oyster Point Pharmaceuticals, Princeton, NJ\u00a008540, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"key":"e_1_3_6_3_2","author":"Market Scope","year":"2022","unstructured":"Market Scope. Ophthalmic Comprehensive Reports. 2020 Dry Eye Products Market Report: Global Analysis for 2019 to 2025 (2022). www.market-scope.com\/pages\/reports\/219\/2020-dry-eye-products-market-report-a-global-analysis-for-2019-to-2025-october-2020 (Accessed: 18 August 2021).","journal-title":"Ophthalmic Comprehensive Reports. 2020 Dry Eye Products Market Report: Global Analysis for 2019 to 2025"},{"issue":"4","key":"e_1_3_6_4_2","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.ajo.2013.12.023","article-title":"Dry eye in the beaver dam offspring study: prevalence, risk factors, and health-related quality of life","volume":"157","author":"Paulsen AJ","year":"2014","unstructured":"Paulsen AJ, Cruickshanks KJ, Fischer ME Dry eye in the beaver dam offspring study: prevalence, risk factors, and health-related quality of life. Am. J. Ophthalmol. 157(4), 799\u2013806 (2014).","journal-title":"Am. J. Ophthalmol."},{"issue":"3","key":"e_1_3_6_5_2","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","article-title":"TFOS DEWS II Epidemiology Report","volume":"15","author":"Stapleton F","year":"2017","unstructured":"Stapleton F, Alves M, Bunya VY TFOS DEWS II Epidemiology Report. Ocul. Surf. 15(3), 334\u2013365 (2017).","journal-title":"Ocul. Surf."},{"issue":"23","key":"e_1_3_6_6_2","doi-asserted-by":"crossref","first-page":"9271","DOI":"10.3390\/ijms21239271","article-title":"Defining dry eye from a clinical perspective","volume":"21","author":"Tsubota K","year":"2020","unstructured":"Tsubota K, Pflugfelder SC, Liu Z Defining dry eye from a clinical perspective. Int. J. Mol. Sci. 21(23), 9271 (2020).","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"e_1_3_6_7_2","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/01.ico.0000133997.07144.9e","article-title":"The lack of association between signs and symptoms in patients with dry eye disease","volume":"23","author":"Nichols KK","year":"2004","unstructured":"Nichols KK, Nichols JJ, Mitchell GL. The lack of association between signs and symptoms in patients with dry eye disease. Cornea 23(8), 762\u2013770 (2004).","journal-title":"Cornea"},{"key":"e_1_3_6_8_2","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2147\/OPTH.S89700","article-title":"Associations between signs and symptoms of dry eye disease: a systematic review","volume":"9","author":"Bartlett JD","year":"2015","unstructured":"Bartlett JD, Keith MS, Sudharshan L, Snedecor SJ. Associations between signs and symptoms of dry eye disease: a systematic review. Clin. Ophthalmol. 9, 1719\u20131730 (2015).","journal-title":"Clin. Ophthalmol."},{"issue":"1","key":"e_1_3_6_9_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.optom.2020.10.002","article-title":"Why the symptoms and objective signs of dry eye disease may not correlate","volume":"14","author":"McMonnies CW","year":"2021","unstructured":"McMonnies CW. Why the symptoms and objective signs of dry eye disease may not correlate. J. Optom. 14(1), 3\u201310 (2021).","journal-title":"J. Optom."},{"issue":"2","key":"e_1_3_6_10_2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00003226-200203000-00001","article-title":"The clinical efficacy of silicone punctal plug therapy","volume":"21","author":"Tai MC","year":"2002","unstructured":"Tai MC, Cosar CB, Cohen EJ, Rapuano CJ, Laibson PR. The clinical efficacy of silicone punctal plug therapy. Cornea 21(2), 135\u2013139 (2002).","journal-title":"Cornea"},{"key":"e_1_3_6_11_2","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/978-1-4615-0717-8_183","article-title":"The effect of punctal occlusion on tear lactoferrin in aqueous deficient dry eye patients","volume":"506","author":"Reese V","year":"2002","unstructured":"Reese V, Youngbar PR. The effect of punctal occlusion on tear lactoferrin in aqueous deficient dry eye patients. Adv. Exp. Med. Biol. 506(Pt B), 1269\u20131271 (2002).","journal-title":"Adv. Exp. Med. Biol."},{"key":"e_1_3_6_12_2","doi-asserted-by":"crossref","first-page":"109101","DOI":"10.1016\/j.exer.2022.109101","article-title":"Biochemistry of human tear film: a review","volume":"220","author":"Masoudi S","year":"2022","unstructured":"Masoudi S. Biochemistry of human tear film: a review. Exp. Eye Res. 220, 109101 (2022).","journal-title":"Exp. Eye Res."},{"issue":"4","key":"e_1_3_6_13_2","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jtos.2017.08.003","article-title":"TFOS DEWS II Report Executive Summary","volume":"15","author":"Craig JP","year":"2017","unstructured":"Craig JP, Nelson JD, Azar DT TFOS DEWS II Report Executive Summary. Ocul. Surf. 15(4), 802\u2013812 (2017).","journal-title":"Ocul. Surf."},{"key":"e_1_3_6_14_2","article-title":"New Drug Application (NDA) 21-023","author":"Center for Drug Revolution and Research","year":"2002","unstructured":"Center for Drug Revolution and Research. New Drug Application (NDA) 21-023. Medical Review(s), (2002). www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2003\/21-023_Restasis_Medr.pdf (Accessed: 6 May 2022).","journal-title":"Medical Review(s)"},{"key":"e_1_3_6_15_2","article-title":"New Drug Application (NDA) 208073Orig1s000","author":"Center for Drug Revolution and Research","year":"2016","unstructured":"Center for Drug Revolution and Research. New Drug Application (NDA) 208073Orig1s000. Statistical Review(s), (2016). www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/208073Orig1s000StatR.pdf (Accessed: 6 May 2022).","journal-title":"Statistical Review(s)"},{"issue":"4","key":"e_1_3_6_16_2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","article-title":"Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase III Study Group","volume":"107","author":"Sall K","year":"2000","unstructured":"Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase III Study Group. Ophthalmology 107(4), 631\u2013639 (2000).","journal-title":"Ophthalmology"},{"key":"e_1_3_6_17_2","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2147\/OPTH.S233194","article-title":"Treatment satisfaction among patients using anti-inflammatory topical medications for dry eye disease","volume":"14","author":"White DE","year":"2020","unstructured":"White DE, Zhao Y, Jayapalan H Treatment satisfaction among patients using anti-inflammatory topical medications for dry eye disease. Clin. Ophthalmol. 14, 875\u2013883 (2020).","journal-title":"Clin. Ophthalmol."},{"key":"e_1_3_6_18_2","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.2147\/OPTH.S226168","article-title":"Real-world treatment patterns of cyclosporine ophthalmic emulsion and lifitegrast ophthalmic solution among patients with dry eye","volume":"13","author":"White DE","year":"2019","unstructured":"White DE, Zhao Y, Ogundele A Real-world treatment patterns of cyclosporine ophthalmic emulsion and lifitegrast ophthalmic solution among patients with dry eye. Clin. Ophthalmol. 13, 2285\u20132292 (2019).","journal-title":"Clin. Ophthalmol."},{"issue":"9","key":"e_1_3_6_19_2","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1177\/0308022616643101","article-title":"Difficulty in eye drop administr ion for people with rheumatoid arthritis","volume":"79","author":"Adamson E","year":"2016","unstructured":"Adamson E, Kendall G. Difficulty in eye drop administr ion for people with rheumatoid arthritis. Br. J. Occup. Ther. 79(9), 550\u2013556 (2016).","journal-title":"Br. J. Occup. Ther."},{"issue":"11","key":"e_1_3_6_20_2","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.jcrs.2014.02.037","article-title":"Evaluation of eyedrop administration by inexperienced patients after cataract surgery","volume":"40","author":"An JA","year":"2014","unstructured":"An JA, Kasner O, Samek DA, L\u00e9vesque V. Evaluation of eyedrop administration by inexperienced patients after cataract surgery. J. Cataract Refract. Surg. 40(11), 1857\u20131861 (2014).","journal-title":"J. Cataract Refract. Surg."},{"issue":"3","key":"e_1_3_6_21_2","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.survophthal.2016.12.009","article-title":"Aids for eye drop administration","volume":"62","author":"Davies I","year":"2017","unstructured":"Davies I, Williams AM, Muir KW. Aids for eye drop administration. Surv. Ophthalmol. 62(3), 332\u2013345 (2017).","journal-title":"Surv. Ophthalmol."},{"issue":"4","key":"e_1_3_6_22_2","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jaapos.2015.05.010","article-title":"The psychological impact of eyedrops administration in children","volume":"19","author":"Sujuan JL","year":"2015","unstructured":"Sujuan JL, Handa S, Perera C, Chia A. The psychological impact of eyedrops administration in children. J. AAPOS 19(4), 338\u2013343 (2015).","journal-title":"J. AAPOS"},{"issue":"2","key":"e_1_3_6_23_2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1124\/jpet.112.194852","article-title":"Varenicline is a potent partial agonist at \u03b16\u03b22* nicotinic acetylcholine receptors in rat and monkey striatum","volume":"342","author":"Bordia T","year":"2012","unstructured":"Bordia T, Hrachova M, Chin M, McIntosh JM, Quik M. Varenicline is a potent partial agonist at \u03b16\u03b22* nicotinic acetylcholine receptors in rat and monkey striatum. J. Pharmacol. Exp. Ther. 342(2), 327\u2013334 (2012).","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"e_1_3_6_24_2","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1124\/mol.106.025130","article-title":"Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors","volume":"70","author":"Mihalak KB","year":"2006","unstructured":"Mihalak KB, Carroll FI, Luetje CW. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol. Pharmacol. 70(3), 801\u2013805 (2006).","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"e_1_3_6_25_2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/chemse\/25.1.61","article-title":"Evidence for nicotinic acetylcholine receptors on nasal trigeminal nerve endings of the rat","volume":"25","author":"Alimohammadi H","year":"2000","unstructured":"Alimohammadi H, Silver WL. Evidence for nicotinic acetylcholine receptors on nasal trigeminal nerve endings of the rat. Chem. Senses 25(1), 61\u201366 (2000).","journal-title":"Chem. Senses"},{"issue":"1639","key":"e_1_3_6_26_2","first-page":"198","article-title":"Varenicline nasal spray (Tyrvaya) for dry eye disease","volume":"63","year":"2021","unstructured":"Varenicline nasal spray (Tyrvaya) for dry eye disease. Med. Lett. Drugs Ther. 63(1639), 198\u2013199 (2021).","journal-title":"Med. Lett. Drugs Ther."},{"issue":"10","key":"e_1_3_6_27_2","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1097\/ICO.0000000000002941","article-title":"ONSET-1 Phase IIb randomized trial to evaluate the safety and efficacy of OC-01 (varenicline solution) nasal spray on signs and symptoms of dry eye disease","volume":"41","author":"Wirta D","year":"2022","unstructured":"Wirta D, Torkildsen G, Boehmer B ONSET-1 Phase IIb randomized trial to evaluate the safety and efficacy of OC-01 (varenicline solution) nasal spray on signs and symptoms of dry eye disease. Cornea 41(10), 1207\u20131216 (2022).","journal-title":"Cornea"},{"key":"e_1_3_6_28_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jtos.2021.12.007","article-title":"A phase II randomized trial to evaluate the long-term (12-week) efficacy and safety of OC-01 (varenicline solution) nasal spray for dry eye disease: the MYSTIC study","volume":"24","author":"Quiroz-Mercado H","year":"2021","unstructured":"Quiroz-Mercado H, Hernandez-Quintela E, Chiu KH, Henry E, Nau JA. A phase II randomized trial to evaluate the long-term (12-week) efficacy and safety of OC-01 (varenicline solution) nasal spray for dry eye disease: the MYSTIC study. Ocul. Surf. 24, 15\u201321 (2021).","journal-title":"Ocul. Surf."},{"issue":"4","key":"e_1_3_6_29_2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ophtha.2021.11.004","article-title":"Efficacy and safety of OC-01 (varenicline solution) nasal spray on signs and symptoms of dry eye disease: the ONSET-2 Phase III randomized trial","volume":"129","author":"Wirta D","year":"2022","unstructured":"Wirta D, Vollmer P, Paauw J ONSET-2 Study Group. Efficacy and safety of OC-01 (varenicline solution) nasal spray on signs and symptoms of dry eye disease: the ONSET-2 Phase III randomized trial. Ophthalmology 129(4), 379\u2013387 (2022).","journal-title":"Ophthalmology"},{"issue":"2","key":"e_1_3_6_30_2","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1080\/08164622.2021.1945410","article-title":"Dry eye disease: an (in)convenient truth","volume":"105","author":"Tavakoli A","year":"2022","unstructured":"Tavakoli A, Flanagan JL. Dry eye disease: an (in)convenient truth. Clin. Exp. Optom. 105(2), 222\u2013229 (2022).","journal-title":"Clin. Exp. Optom."},{"issue":"2","key":"e_1_3_6_31_2","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3390\/jcm11020367","article-title":"Adherence to eye drops usage in dry eye patients and reasons for non-compliance: a web-based survey","volume":"11","author":"Uchino M","year":"2022","unstructured":"Uchino M, Yokoi N, Shimazaki J, Hori Y, Tsubota K, Japan Dry Eye Society. Adherence to eye drops usage in dry eye patients and reasons for non-compliance: a web-based survey. J. Clin. Med. 11(2), 367 (2022).","journal-title":"J. Clin. Med."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2022-0215","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T10:51:44Z","timestamp":1685530304000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2022-0215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.57264\/cer-2022-0215"],"URL":"https:\/\/doi.org\/10.57264\/cer-2022-0215","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]},"article-number":"e220215"}}